

Application No. 09/944,564 Page 12
Nassief

Inventor: Nida Abdul-Ghani

CLAIMS

1 – 24. (Withdrawn)

25. (New) A pharmaceutical composition consisting essentially of glycoposphopeptical for oral administration for the treatment of allergy and asthma in dosage and duration which is effective to:

- i- Switch-off the airway eosinophilic inflammation.
- ii- Reduce mucus secretion.
- iii- Reduce symptom scores significantly.
- iv- Restore airways patency as measured by Pulmonary Function Test.

26. (New) A pharmaceutical composition of claim 25, to induce a clinical remission and long-term therapeutic effect in a chronically ill patient.

27. (New) A method of treatment of allergy and asthma patients in need of multiple drugs daily, comprising of administering the pharmaceutical composition of claim 25 for a short course of 1-14 days to induce a remission of 3-12 months.

28. (New) A pharmaceutical composition for the treatment of allergy and asthma consisting essentially of the herbal seeds of *Nigella sativa* to act as a vaccine that is almost identical to Purified Protein Derivative from *Bacillus Calmette Guréin*:

- i- Switch-off the airway eosinophilic inflammation.
- ii- Reduce mucus secretion.
- iii- Reduce symptom scores significantly.
- iv- Restore airways patency as measured by Pulmonary Function Test.

29. (New) A pharmaceutical composition vaccine of claim 28, to induce a clinical remission and long-term therapeutic effect in a chronically ill patient suffering from asthma and allergy.

30. (New) A method of treatment of allergy and asthma patients in need of multiple drugs daily, comprising of administering the pharmaceutical composition of claim 28 for a short course of 1-14 days to induce a remission of 3-12 months.

31. (New) A pharmaceutical composition vaccine from *Nigella sativa*, to induce a clinical remission and long-term therapeutic effect in patients with Crohn's disease.

32. (New) A method of treatment of Crohn's disease, comprising of administering the pharmaceutical composition vaccine from *Nigella sativa* for a short course of 1-14 days to induce symptomatic remission.

33. (New) A pharmaceutical composition vaccine from *Nigella sativa*, to induce a clinical remission and long-term therapeutic effect in patients with influenza and common cold.

34. (New) A method of treatment of influenza and common cold, comprising of administering the pharmaceutical composition vaccine from *Nigella sativa* for a short course of 1-14 days to induce symptomatic remission.